This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letters to the Editor

Aripiprazole Joins the Family of Second-Generation Mood Stabilizers

Janusz K. Rybakowski, MD, PhD

Published: May 11, 2008

Article Abstract

Letter to the Editor

Sir: In my recent letter to the International Journal of Neuropsychopharmacology, I proposed a modified definition of the mood stabilizer as "a drug that if used as monotherapy (1)acts therapeutically in mania or/and in depression, (2) acts prophylactically against manic or/and depressive episodes as demonstrated in a trial of at least 1 year’s duration, and (3) does not worsen any therapeutic or prophylactic aspect of the illness outlined above." On the basis of a recent trial by Keck et al. published in this journal, it is evident that aripiprazole meets these criteria.

The introduction of individual mood stabilizers occurred more than 4 decades ago.

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 69

Quick Links: Bipolar Disorder , Mood Disorders


Sign-up to stay
up-to-date today!


Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...